238 Views

Madison Dearborn to acquire Patterson Medical for about $715 mln

Madison Dearborn Partners has agreed to buy Patterson Companies Inc‘s medical business Patterson Medical for about $715 million in cash. The transaction is expected to be completed in the fiscal second quarter. BofA Merrill Lynch served as financial advisor to Patterson Companies while Barclays and Deutsche Bank advised MDP.

Sumitomo Mitsui Banking to buy GE’s European Sponsor Finance for $2.2 bln

GE said Tuesday that it has agreed to sell its European Sponsor Finance business to Sumitomo Mitsui Banking Corp. Europe Ltd., a  subsidiary of Sumitomo Mitsui Banking Corp., for about $2.2 billion. The GE business provides sponsor finance for European mid-market private equity deals. GE Capital is keeping its $1 billion investment in the European Senior Secured Loan Programme and European Loan Programme, both joint ventures between GE Capital and Ares Capital. The deal is expected to close in third quarter. Bank of America Merrill Lynch and Citigroup Global Markets advised GE.

152 Views

Lone Star Funds to buy Home Properties in $7.6 bln take-private deal

Lone Star Funds has agreed to acquire Home Properties Inc in a take-private deal valued at about $7.6 billion. The transaction is expected to be completed during the fourth quarter of this year. BofA Merrill Lynch served as financial advisor to Home Properties while Goldman Sachs.did likewise for Lone Star. Home Properties Inc owns, operates, acquires and repositions apartment communities in major metropolitan suburbs.

108 Views

VC-backed ProNAi files for IPO

Vancouver-based ProNAi Therapeutics, a developer of nucleic acid therapeutics, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The stock will list on the NASDAQ under the ticker symbol “DNAI.” Jefferies LLC and BofA Merrill Lynch will serve as the lead underwriters. ProNAi’s backers include Vivo Capital, Frazier Healthcare Ventures, OrbiMed Advisors, Adams Street Partners, RA Capital Management, Caxton Alternative Management, Hopen Life Science Ventures, Sectoral Asset Management and Janus Capital Management.

413 Views

CD&R-backed Univar prices IPO

Chemicals distributor Univar Inc has priced its IPO of 20 million shares at between $20 and $22 per share. Deutsche Bank Securities, Goldman, Sachs & Co and BofA Merrill Lynch are serving as the lead underwriters. Univar’s backers include Clayton, Dubilier & Rice LLP and CVC Capital Partners.

167 Views

PE-backed EndoChoice goes public

EndoChoice, an Atlanta area-based provider of endoscopy products and services, has debuted its IPO after pricing its 6.35 million shares at $15 per share. The stock began trading Friday on the NYSE under the ticker symbol “GI.” JP Morgan and BofA Merrill Lynch are the lead underwriters. EndoChoice’s backers include Council Capital and River Cities Capital Funds.

136 Views

VC-backed Alarm.com files for IPO

Vienna, Virginia-based Alarm.com Holdings, a connected home platform solution, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The company plans on trading the stock on the NASDAQ under the ticker symbol “ALRM.” Goldman, Sachs & Co, Credit Suisse Securities LLC and BofA Merrill Lynch are serving as the lead underwriters. Alarm.com’s backers include ABS Capital and Technology Crossover Ventures.

131 Views

Fortress-owned FTAI debuts IPO

Fortress Transportation and Infrastructure Investors LLC, which owns and acquires transportation-related infrastructure and equipment, has raised $34 million for its IPO after pricing its 20 million shares at $17 per share. The stock began trading Friday on the NYSE under the ticker symbol “FTAI.” Citigroup Global Markets Inc., BofA Merrill Lynch, Barclays Capital Inc, Deutsche Bank Securities Inc and UBS Securities LLC are the lead underwriters. FTAI is owned by Fortress Investment Group.

305 Views

VC-backed Glaukos Corp files for IPO

Laguna Hills, California-based Glaukos Corporation, a developer of treatments for glaucoma, has filed for an IPO. The number of shares that will be sold as well as the IPO’s pricing terms have yet to be set. The company plans on trading the stock on the NYSE under the ticker symbol “GKOS.” J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co are serving as the lead underwriters. Glaukos’ backers include OrbiMed Advisors, Frazier Healthcare Ventures, InterWest Partners, Domain Associates, Fjord Ventures, Montreaux Equity Partners and Versant Ventures

VC-backed Adaptimmune rolls out IPO

UK and Philadelphia-based biotechnology company Adaptimmune Therapeutics plc has debuted its IPO after pricing its 11.25 million shares at $17 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “ADAP.” BofA Merrill Lynch, Cowen and Company and Leerink Partners LLC are serving as the lead underwriters. Adaptimmune’s backers include New Enterprise Associates, OrbiMed Advisors, Wellington Management Company, Fidelity Biosciences, Foresite Capital Management, Ridgeback Capital Management and Rock Springs Capital.

207 Views

PE-owned restaurant chain Bojangles sets IPO pricing terms

Restaurant chain Bojangles Inc will be selling 6.25 million shares of its IPO at between $15 and $17 per share. The company will list the stock on the NASDAQ under the ticker symbol “BOJA.” BofA Merrill Lynch, Wells Fargo Securities and Jefferies are serving as the lead underwriters. Bojangles is a portfolio company of Advent International.

137 Views

CCMP-backed Milacron files to go public

Milacron Holdings Corp. has filed to raise up to $100 million via initial public offering. Milacron is a Cincinnati-based plastics processing and industrial fluids company that is owned by CCMP Capital Advisors. Milacron did not disclose the shares it would offer or their price range. BofA Merrill Lynch, Barclays and J.P. Morgan are acting as joint lead book-runners on the IPO.

278 Views

Insight Venture Partners to acquire E2open for about $273 mln

Insight Venture Partners has agreed to buy E2open Inc for about $273 million. BofA Merrill Lynch is serving as financial advisor to E2open on the transaction. Based in Foster City, California, E2open is a provider of cloud-based solutions for collaborative planning and execution across global trading networks.

105 Views

VC-backed Ascendis Pharma goes public

Danish biotech firm Ascendis Pharma has raised $108 million for its IPO after pricing its 6 million shares at $18 per share. The stock begins trading Wednesday on the NASDAQ under the ticker symbol “ASND.” BofA Merrill Lynch and Leerink Partners are serving as the lead underwriters. Ascendis Pharma’s backers include Sofinnova Ventures, OrbiMed, Vivo Capital, Venrock, RA Capital Management and Janus Capital Management.

PE HUB Community

Join the 12519 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget